Association Between Early Heparin Prophylaxis and Risk of Venous Thromboembolism Through Two Months After Spine Fusion for Spinal Metastasis: A Retrospective Cohort Study of United States Academic Health Centers.

IF 2.6 3区 医学 Q2 CLINICAL NEUROLOGY
Anthony N Baumann, Robert J Trager, Omkar Anaspure, John T Strony, Aditya Muralidharan, Tyler Sanda, Jacob C Hoffmann
{"title":"Association Between Early Heparin Prophylaxis and Risk of Venous Thromboembolism Through Two Months After Spine Fusion for Spinal Metastasis: A Retrospective Cohort Study of United States Academic Health Centers.","authors":"Anthony N Baumann, Robert J Trager, Omkar Anaspure, John T Strony, Aditya Muralidharan, Tyler Sanda, Jacob C Hoffmann","doi":"10.1177/21925682251330261","DOIUrl":null,"url":null,"abstract":"<p><p>Study DesignRetrospective Cohort Study.ObjectiveEvidence on chemoprophylactic anticoagulation efficacy in preventing venous thromboembolism (VTE) after spine surgery for metastasis is scarce. We hypothesized that early heparin administration (0-2 days post-surgery) significantly reduces VTE risk post-arthrodesis. We also examined VTE incidence and risk over 2 months and severe postoperative bleeding (SPOB).MethodsWe conducted a retrospective cohort study using the TriNetX network, identifying adults who had a spinal arthrodesis for spinal metastasis in the past 20 years. Patients were grouped by anticoagulation use: a heparin cohort and a non-anticoagulated control. After propensity matching for key VTE risk factors, we examined VTE risk ratios (RR) with 95% confidence intervals (CI) up to 2 weeks post-surgery, and incidence and RR of VTE and SPOB over 2 months.ResultsThere were 847 patients per cohort after matching. There was no statistically significant difference in incidence of VTE in the heparin group compared to the no anticoagulation cohort through 2-weeks' (4.0% vs 2.7%; RR: 1.48; 95% CI: 0.88, 2.49; <i>P</i> = 0.1383) and 2 months' follow-up (9.4% vs 7.9%; RR: 1.2; 95% CI: 0.88, 1.63; <i>P</i> = 0.2619). Furthermore, there was no statistically significant difference in incidence of SPOB in the heparin group compared to the no anticoagulation group at 2-weeks' (1.5% vs 1.7%; RR: 0.93; 95% CI: 0.44, 1.96; <i>P</i> = 0.8462) and 2-months' follow-up (2.8% vs 2.5%; RR: 1.1; 95% CI: 0.64, 2.04; <i>P</i> = 0.6504).ConclusionEarly heparin administration did not significantly affect VTE or SPOB rates compared to controls. Future research should explore whether other anticoagulants lower VTE risk post-spinal metastasis fusion.</p>","PeriodicalId":12680,"journal":{"name":"Global Spine Journal","volume":" ","pages":"21925682251330261"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11948240/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Spine Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/21925682251330261","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Study DesignRetrospective Cohort Study.ObjectiveEvidence on chemoprophylactic anticoagulation efficacy in preventing venous thromboembolism (VTE) after spine surgery for metastasis is scarce. We hypothesized that early heparin administration (0-2 days post-surgery) significantly reduces VTE risk post-arthrodesis. We also examined VTE incidence and risk over 2 months and severe postoperative bleeding (SPOB).MethodsWe conducted a retrospective cohort study using the TriNetX network, identifying adults who had a spinal arthrodesis for spinal metastasis in the past 20 years. Patients were grouped by anticoagulation use: a heparin cohort and a non-anticoagulated control. After propensity matching for key VTE risk factors, we examined VTE risk ratios (RR) with 95% confidence intervals (CI) up to 2 weeks post-surgery, and incidence and RR of VTE and SPOB over 2 months.ResultsThere were 847 patients per cohort after matching. There was no statistically significant difference in incidence of VTE in the heparin group compared to the no anticoagulation cohort through 2-weeks' (4.0% vs 2.7%; RR: 1.48; 95% CI: 0.88, 2.49; P = 0.1383) and 2 months' follow-up (9.4% vs 7.9%; RR: 1.2; 95% CI: 0.88, 1.63; P = 0.2619). Furthermore, there was no statistically significant difference in incidence of SPOB in the heparin group compared to the no anticoagulation group at 2-weeks' (1.5% vs 1.7%; RR: 0.93; 95% CI: 0.44, 1.96; P = 0.8462) and 2-months' follow-up (2.8% vs 2.5%; RR: 1.1; 95% CI: 0.64, 2.04; P = 0.6504).ConclusionEarly heparin administration did not significantly affect VTE or SPOB rates compared to controls. Future research should explore whether other anticoagulants lower VTE risk post-spinal metastasis fusion.

早期肝素预防与脊柱融合术后2个月静脉血栓栓塞风险之间的关系:美国学术健康中心的回顾性队列研究
研究设计:回顾性队列研究。目的探讨化疗预防抗凝在预防脊柱手术转移后静脉血栓栓塞(VTE)中的作用。我们假设早期给予肝素(术后0-2天)可显著降低关节融合术后静脉血栓栓塞的风险。我们还检查了静脉血栓栓塞的发生率和超过2个月的风险以及严重的术后出血(SPOB)。方法:我们使用TriNetX网络进行了一项回顾性队列研究,确定了过去20年中因脊柱转移而进行脊柱融合术的成年人。患者按抗凝治疗分组:肝素组和非抗凝对照组。在对关键静脉血栓栓塞危险因素进行倾向匹配后,我们检查了术后2周静脉血栓栓塞风险比(RR), 95%置信区间(CI),以及2个月内静脉血栓栓塞和SPOB的发病率和RR。结果匹配后每组847例患者。在2周内,肝素组静脉血栓栓塞发生率与无抗凝治疗组相比无统计学差异(4.0% vs 2.7%;RR: 1.48;95% ci: 0.88, 2.49;P = 0.1383)和2个月随访(9.4% vs 7.9%;RR: 1.2;95% ci: 0.88, 1.63;P = 0.2619)。此外,肝素组与无抗凝治疗组在2周时SPOB发生率无统计学差异(1.5% vs 1.7%;RR: 0.93;95% ci: 0.44, 1.96;P = 0.8462)和2个月随访(2.8% vs 2.5%;RR: 1.1;95% ci: 0.64, 2.04;P = 0.6504)。结论与对照组相比,早期给药肝素对静脉血栓栓塞和SPOB发生率无显著影响。未来的研究应探讨其他抗凝剂是否能降低脊髓转移融合后静脉血栓栓塞的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Global Spine Journal
Global Spine Journal Medicine-Surgery
CiteScore
6.20
自引率
8.30%
发文量
278
审稿时长
8 weeks
期刊介绍: Global Spine Journal (GSJ) is the official scientific publication of AOSpine. A peer-reviewed, open access journal, devoted to the study and treatment of spinal disorders, including diagnosis, operative and non-operative treatment options, surgical techniques, and emerging research and clinical developments.GSJ is indexed in PubMedCentral, SCOPUS, and Emerging Sources Citation Index (ESCI).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信